PD-1/PD-L1-IN-NP19|CAS 2377916-66-8|DC Chemicals

Cas No.:	2377916-66-8
Chemical Name:	PD-1/PD-L1-IN-NP19
Synonyms:	PD-1/PD-L1-IN-NP19;2-[[5-chloro-2-[(3-cyanophenyl)methoxy]-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]-2-methylpropanoic acid;N-[[5-chloro-2-[(3-cyanophenyl)methoxy]-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-2-methyl-alanine;BDBM50542954;HY-131347;NP19;CHEMBL4639202;EX-A7967;MS-30121;G17758;CS-0133450;AKOS040755511;2377916-66-8;Alanine, N-[[5-chloro-2-[(3-cyanophenyl)methoxy]-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-2-methyl-
SMILES:	ClC1=C(C([H])=C(C(=C1[H])C([H])([H])N([H])C(C(=O)O[H])(C([H])([H])[H])C([H])([H])[H])OC([H])([H])C1C([H])=C([H])C([H])=C(C#N)C=1[H])OC([H])([H])C1C([H])=C([H])C([H])=C(C2C([H])=C([H])C([H])=C([H])C=2[H])C=1C([H])([H])[H]
Formula:	C₃₃H₃₁ClN₂O₄
M.Wt:	555.0632
Purity:	98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

COA

Cat. No.	Product name	Field of application
DC49130	PD-1/PD-L1-IN-23	PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester prodrug of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice.
DC44157	PD-1/PD-L1-IN-NP19	PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects.
DC44154	PD-1/PD-L1-IN 3	PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases.
DC42714	BMS-8	BMS-8 inhibits the PD-1/PD-L1 interaction with IC50 of 7.2 μM. BMS-8, binds directly to PD-L1 and induces formation of PD-L1 homodimers, which in turn prevents the interaction with PD-1[1].
DC12058	BMS-1166 (PD-1/PD-L1-IN1)	BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 1.4 nM.